Last $413.00 USD
Change Today +3.25 / 0.79%
Volume 818.4K
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (REGN) Snapshot

Open
$416.37
Previous Close
$409.75
Day High
$416.49
Day Low
$408.48
52 Week High
11/19/14 - $419.27
52 Week Low
12/18/13 - $257.69
Market Cap
42.0B
Average Volume 10 Days
796.3K
EPS TTM
$3.04
Shares Outstanding
99.7M
EX-Date
--
P/E TM
135.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (REGN)

regeneron pharmaceuticals (REGN) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company’s antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.

2,714 Employees
Last Reported Date: 11/4/14
Founded in 1988

regeneron pharmaceuticals (REGN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $194.2K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $2.6M
Senior Vice President of Research & Developme...
Total Annual Compensation: $863.0K
Senior Vice President of Commercial
Total Annual Compensation: $814.5K
Compensation as of Fiscal Year 2013.

regeneron pharmaceuticals (REGN) Key Developments

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. In the study, the three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second at Week 12 in patients with high blood eosinophils, as compared to placebo in combination with standard-of-care therapy. In addition, two doses of dupilumab showed a statistically significant improvement in mean percentage change in FEV1, as well as a reduction in severe exacerbations, in both the high eosinophils and overall study population. In the high eosinophils patient group: Mean improvements from baseline in FEV1 at 12 weeks, the primary endpoint of the study were: 390ml dupilumab 300 mg every other week; 430 ml dupilumab 200 mg Q2W; 180 ml placebo. In the overall population: Mean improvements from baseline in FEV1 at 12 weeks were: 280 ml dupilumab 300 mg Q2W; 310 ml dupilumab 200 mg Q2W; 120 ml placebo. In both the high eosinophils patient group and overall patient group: Dupilumab showed a reduction in adjusted annualized rate of severe exacerbations compared to placebo. These results were based on a pre-specified interim analysis, which occurred when all patients had reached Week 12 of the 24-week treatment period; the average treatment duration at the time of the analysis was 21.5 weeks. The final analyses on exacerbations and safety will occur at 24 weeks. The most common adverse event was injection site reaction, which was more frequent in the four dupilumab dose groups compared to placebo. Other common adverse events in the study included upper respiratory tract infection, headache, nasopharyngitis and bronchitis. The incidence of infections was balanced across treatment groups, as was the incidence of serious adverse events. The double-blind, placebo-controlled, 24-week, dose-ranging study enrolled 776 adult patients with moderate-to-severe uncontrolled asthma, as defined by the Global Initiative for Asthma 2014 Guidelines. Trial participants were randomized to receive one of four doses of dupilumab or placebo. Approximately 40% of patients had high eosinophils across the dose groups. During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist combination product. Patients can administer inhaled rescue medication as needed during the study. The 24-week treatment period of the study is ongoing, and patients will be followed for 16 weeks after treatment. Full results of the trial will be presented at an upcoming scientific meeting.

Regeneron Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Regeneron Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's revenues were $725,788,000 compared to $597,027,000 a year ago. Income from operations was $182,719,000 compared to $236,802,000 a year ago. Income before income taxes was $176,078,000 compared to $225,684,000 a year ago. Net income was $79,720,000 or $0.70 per diluted share compared to $141,306,000 or $1.25 per diluted share a year ago. Non-GAAP net income was $295,117,000 or $2.52 per diluted share compared to $277,252,000 or $2.40 per diluted share a year ago. For the nine months, the company's revenues were $2,017,228,000 compared to $1,494,333,000 a year ago. Income from operations was $591,064,000 compared to $547,955,000 a year ago. Income before income taxes was $554,460,000 compared to $515,207,000 a year ago. Net income was $237,898,000 or $2.10 per diluted share compared to $327,556,000 or $2.95 per diluted share a year ago. Non-GAAP net income was $847,077,000 or $7.22 per diluted share compared to $675,563,000 or $5.92 per diluted share a year ago. Capital expenditures were $215 million. The company provided earnings guidance for the year 2014. The company expects capital expenditures to be in the range of $300 million to $350 million compared to previously provided guidance of $350 million to $425 million. Net sales guidance to $1.7 billion to $1.74 billion from the previously provided range of $1.7 billion to $1.8 million.

Regeneron Pharmaceuticals, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014

Regeneron Pharmaceuticals, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014. Venue: Apella, 450 East 29th Street, New York, New York, United States. Presentation Date & Speakers: Nov-12-2014, George Yancopoulos, George D. Yancopoulos, Chief Scientific Officer, Executive Vice President, Director, Ex Officio Member of Technology Committee and President of Regeneron Research Laboratories.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $413.00 USD +3.25

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $192.77 USD -1.38
BioMarin Pharmaceutical Inc $89.45 USD +1.51
Kyowa Hakko Kirin Co Ltd ¥1,295 JPY +11.00
UCB SA €61.66 EUR +0.66
Vertex Pharmaceuticals Inc $114.19 USD +0.39
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 100.0x
Price/Sales 15.5x
Price/Book 16.0x
Price/Cash Flow 123.1x
TEV/Sales 15.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.